Key result
Post-TAVI antithrombotic therapy lacks high-grade evidence, requiring individualized treatment based on patient characteristics.
Why the study?
The optimal antithrombotic regimen following TAVI remains uncertain, as antithrombotic therapy to prevent thrombotic complications exposes patients to bleeding risks and current clinical guidelines rely mostly on low-grade evidence.
What is the optimal antithrombotic pharmacotherapy regimen following transcatheter aortic valve implantation (TAVI)?
What is the optimal antithrombotic pharmacotherapy regimen following transcatheter aortic valve implantation (TAVI)?
This review highlights the uncertainty in optimal antithrombotic therapy post-TAVI and emphasizes individualized treatment pending further RCT data.
Answers are grounded in this paper and cite their sources.
Individualized antithrombotic therapy remains preferred post-TAVI; leaves open optimal regimen until RCTs report.
Introduction: Transcatheter aortic valve implantation (TAVI) is the treatment of choice for a large proportion of patients with severe aortic stenosis. Despite numerous technological and clinical advances, TAVI remains associated with thrombotic complications requiring antithrombotic pharmacotherapy, which exposes to the risk of bleeding, especially in elderly individuals. The optimal antithrombotic regimen following TAVI is uncertain and several investigations are ongoing.Areas covered: Clinical guidelines are mostly driven by observational trials and experts’ opinions, thus resulting into low-grade level of evidence. The aim of the current review is to critically explore the epidemiology, pathophysiology and prognostic value of thrombotic and bleeding events after TAVI, and to review the current literature on antithrombotic strategies following the procedure.Expert opinion: Thrombotic and bleeding events remain major complications occurring in the frail population that is currently offered TAVI. Waiting for upcoming evidence from ongoing randomized clinical trials, tailoring antithrombotic therapies based on patients’ characteristics, values and circumstances is a preferable approach.
No takes yet. Share an insight, caveat, or question.
Greco et al. (2019) conducted a review in Severe aortic stenosis post-TAVI. Antithrombotic pharmacotherapy was evaluated. Antithrombotic pharmacotherapy following TAVI currently lacks high-grade evidence, making individualized therapy based on patient characteristics the preferred approach while awaiting trial data.
Synapse has enriched 10 related papers. Consider them for comparative context: